Advice

following an abbreviated submission

efavirenz (Sustiva®) is accepted for use within NHS Scotland.

Indication under review: antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.

For patients at least 3 months old and weighing at least 3.5kg who cannot swallow capsules, the capsule contents can be administered with a small amount of food using the capsule sprinkle method of administration.

Efavirenz is listed in the British National Formulary for Children for the treatment of HIV infection.

Download detailed advice51KB (PDF)

Download

Medicine details

Medicine name:
efavirenz (Sustiva)
SMC ID:
1125/15
Indication:
antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca
BNF chapter
Infections
Submission type
Abbreviated
Status
Accepted
Date advice published
07 December 2015